GH Research (GHRS) Competitors $13.22 +0.72 (+5.76%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$13.40 +0.18 (+1.36%) As of 09/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. MLYS, IBRX, CPRX, ALVO, OCUL, BLTE, IDYA, AGIO, ANIP, and RXRXShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors Mineralys Therapeutics ImmunityBio Catalyst Pharmaceuticals Alvotech Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals ANI Pharmaceuticals Recursion Pharmaceuticals GH Research (NASDAQ:GHRS) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Which has more volatility & risk, GHRS or MLYS? GH Research has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500. Is GHRS or MLYS more profitable? GH Research's return on equity of -16.71% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% Mineralys Therapeutics N/A -70.44%-65.51% Does the media prefer GHRS or MLYS? In the previous week, Mineralys Therapeutics had 9 more articles in the media than GH Research. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 1 mentions for GH Research. Mineralys Therapeutics' average media sentiment score of 0.60 beat GH Research's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of GHRS or MLYS? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, GHRS or MLYS? GH Research is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-17.86Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-11.20 Do analysts recommend GHRS or MLYS? GH Research presently has a consensus target price of $32.00, suggesting a potential upside of 142.06%. Mineralys Therapeutics has a consensus target price of $43.50, suggesting a potential upside of 9.10%. Given GH Research's stronger consensus rating and higher possible upside, equities analysts plainly believe GH Research is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryGH Research beats Mineralys Therapeutics on 9 of the 13 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$650.35M$3.12B$5.78B$10.27BDividend YieldN/A2.37%5.74%4.64%P/E Ratio-17.8621.3676.7726.98Price / SalesN/A433.30515.78167.34Price / CashN/A45.3237.1760.63Price / Book3.849.6913.486.37Net Income-$38.96M-$52.92M$3.29B$271.46M7 Day Performance10.72%2.19%1.55%2.53%1 Month Performance5.34%8.96%6.80%9.42%1 Year Performance69.49%10.84%77.33%30.16% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research1.7682 of 5 stars$13.22+5.8%$32.00+142.1%+65.5%$650.35MN/A-17.8610MLYSMineralys Therapeutics2.4813 of 5 stars$36.21-2.4%$43.50+20.1%+241.1%$2.46BN/A-10.1728Insider TradeIBRXImmunityBio2.4202 of 5 stars$2.74+5.4%$10.75+292.3%-16.7%$2.46B$14.74M-5.71590High Trading VolumeCPRXCatalyst Pharmaceuticals4.9604 of 5 stars$19.76-1.1%$33.20+68.0%-0.1%$2.44B$491.73M11.9880Positive NewsALVOAlvotech3.3048 of 5 stars$8.12+1.1%$14.00+72.4%-29.4%$2.42B$491.98M35.301,032Positive NewsShort Interest ↓OCULOcular Therapeutix4.0229 of 5 stars$12.54-2.1%$17.83+42.2%+40.4%$2.23B$63.72M-9.80230Positive NewsBLTEBelite Bio2.898 of 5 stars$66.80-3.9%$96.00+43.7%+51.6%$2.21BN/A-43.1010Trending NewsAnalyst UpgradeAnalyst RevisionHigh Trading VolumeIDYAIDEAYA Biosciences4.0045 of 5 stars$24.53-0.3%$42.85+74.7%-24.5%$2.16B$7M-6.4780Analyst ForecastGap UpAGIOAgios Pharmaceuticals4.3447 of 5 stars$36.30-1.3%$56.00+54.3%-16.7%$2.14B$36.50M3.30390Gap UpANIPANI Pharmaceuticals4.0706 of 5 stars$98.81+1.1%$88.25-10.7%+59.7%$2.12B$614.38M-128.32600Analyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals2.185 of 5 stars$4.77-1.2%$7.25+52.0%-28.7%$2.10B$58.84M-2.68400 Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives ImmunityBio Alternatives Catalyst Pharmaceuticals Alternatives Alvotech Alternatives Ocular Therapeutix Alternatives Belite Bio Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GHRS Stock Alerts